Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway

Area of Science:

• Molecular Biology
• Physiology
• Genetics

Background:

• Skeletal muscle atrophy, a debilitating condition, arises from imbalanced protein synthesis and degradation.
• Existing treatments for muscle atrophy are insufficient, necessitating a deeper understanding of its underlying mechanisms.
• Atrophy is associated with injury, disease, disuse, and aging, highlighting the need for effective therapeutic targets.

Purpose of the Study:

• To investigate the role of the mouse ether-a-go-go related gene (Merg1a) K+ channel in skeletal muscle atrophy.
• To explore Merg1a as a potential therapeutic target for preventing or treating muscle atrophy.

Main Methods:

• Examined Merg1a expression in mouse models of muscle atrophy induced by tumor cachexia and hindlimb suspension.
• Investigated the effects of ectopic Merg1a expression and a dysfunctional Merg1a mutant in healthy and atrophied mouse models.
• Assessed the impact of astemizole, a Merg1a channel blocker, on muscle atrophy in hindlimb-suspended mice.
• Analyzed the activation of the ubiquitin-proteasome pathway in response to Merg1a expression.

Main Results:

• Merg1a K+ channel expression was upregulated in skeletal muscle during atrophy caused by malignant tumors and disuse.
• Ectopic Merg1a expression induced atrophy in healthy mice, while a Merg1a mutant suppressed atrophy in disused muscles.
• Astemizole treatment inhibited muscle atrophy in hindlimb-suspended mice.
• Merg1a expression activated the ubiquitin-proteasome pathway, a key driver of protein degradation in muscle atrophy.

Conclusions:

• Upregulation of the Merg1a K+ channel is implicated in the initiation and progression of skeletal muscle atrophy.
• Merg1a likely drives atrophy by activating the ubiquitin-proteasome pathway.
• The Merg1a gene and its protein product represent promising therapeutic targets for combating muscle atrophy.